Immunotherapy and Biomarkers in Neurodegenerative Disorders

Immunotherapy and Biomarkers in Neurodegenerative Disorders PDF Author: Lars Lannfelt
Publisher:
ISBN: 9781493935604
Category : Biochemical markers
Languages : en
Pages : 289

Get Book Here

Book Description

Immunotherapy and Biomarkers in Neurodegenerative Disorders

Immunotherapy and Biomarkers in Neurodegenerative Disorders PDF Author: Lars Lannfelt
Publisher:
ISBN: 9781493935604
Category : Biochemical markers
Languages : en
Pages : 289

Get Book Here

Book Description


Immunological Mechanisms, Biomarkers and Immunotherapies of Alzheimer's Disease

Immunological Mechanisms, Biomarkers and Immunotherapies of Alzheimer's Disease PDF Author: Yu-Hui Liu
Publisher: Frontiers Media SA
ISBN: 2889713644
Category : Science
Languages : en
Pages : 124

Get Book Here

Book Description


Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives

Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives PDF Author: Suman Dutta
Publisher: Frontiers Media SA
ISBN: 2832518001
Category : Science
Languages : en
Pages : 273

Get Book Here

Book Description


Immunotherapy – A Novel Facet of Modern Therapeutics

Immunotherapy – A Novel Facet of Modern Therapeutics PDF Author: Sujata P. Sawarkar
Publisher: Springer Nature
ISBN: 9811590389
Category : Medical
Languages : en
Pages : 267

Get Book Here

Book Description
This book illustrates the significance and relevance of immunotherapy in modern-day therapeutics. Focusing on the application of immunotherapy in oncology, neurodegenerative and autoimmune diseases, it discusses the drug delivery systems, and pre-clinical and clinical methodologies for immunotherapy-based drugs. It also comprehensively reviews various aspects of immunotherapy, such as regulatory affairs, quality control, safety, and pharmacovigilance. Further, the book discusses the in vitro validation of therapeutic strategies prior to patient application and management of immunotherapy-related side effects and presents case studies demonstrating the design and development (pre-clinical to clinical) of immunotherapy for various diseases. It also describes various design considerations and the scale-up synthesis of immunotherapeutics and screening methods. Lastly, it explores the important aspect of cost-effectiveness and rational immunotherapy strategies.

Biomarkers for Huntington's Disease

Biomarkers for Huntington's Disease PDF Author: Elizabeth A. Thomas
Publisher: Springer Nature
ISBN: 3031328159
Category : Medical
Languages : en
Pages : 476

Get Book Here

Book Description
Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents a distinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume is written by top leaders in the field, and takes a cross-disciplinary approach to cover a broad spectrum of biomarker types, in order to provide the latest advances in the development of biochemical, molecular, imaging and digital biomarkers that have been investigated for HD. With the ultimate goal of treating patients, the development of disease-associated biomarkers has never been more important.

Neurodegenerative Diseases

Neurodegenerative Diseases PDF Author: Philip Beart
Publisher: Springer
ISBN: 3319571931
Category : Medical
Languages : en
Pages : 546

Get Book Here

Book Description
Provides a timely overview of critical advances in molecular and cellular neurobiology, covers key methodologies driving progress, and highlights key future directions for research on neuronal injury and neurodegeneration relevant to neuronal brain pathologies. The editors bring together contributions from internationally recognized workers in the field to provide an up to date account of how and why molecular and cellular neurobiology is such an important area for clinical neuroscience. Understanding the molecular aspects of a number of neurodegenerative conditions such as Parkinson's or Alzheimer's disease for the purpose of improving patient management remains a major challenge of neurobiology be it from the basic or clinical perspective. A strategic evaluation of research contributions and the power of modern methods will help advance knowledge over the next years.

Neurodegenerative Diseases

Neurodegenerative Diseases PDF Author: Jeffrey L. Cummings
Publisher: Oxford University Press
ISBN: 0190233567
Category : Medical
Languages : en
Pages : 361

Get Book Here

Book Description
Presents a thorough examination of the unifying principles from the subcellular to the systems and clinical levels; Identifies common themes among molecular biology, genetics, physiology, pathology, biomarkers, behavior, and treatment strategies that are shared between neurodegenerative diseases; Enables better care of patients and help build collaboration across researchers in multiple specializations that could help advance future insights and facilitate novel therapies and enhancing basic scientific understanding of these diseases to a new generation.

Tau oligomers

Tau oligomers PDF Author: Jesus Avila
Publisher: Frontiers E-books
ISBN: 288919261X
Category : Medicine (General)
Languages : en
Pages : 114

Get Book Here

Book Description
Neurofibrillary tangles (NFTs) composed of intracellular aggregates of tau protein are a key neuropathological feature of Alzheimer’s Disease (AD) and other neurodegenerative diseases, collectively termed tauopathies. The abundance of NFTs has been reported to correlate positively with the severity of cognitive impairment in AD. However, accumulating evidences derived from studies of experimental models have identified that NFTs themselves may not be neurotoxic. Now, many of tau researchers are seeking a “toxic” form of tau protein. Moreover, it was suggested that a “toxic” tau was capable to seed aggregation of native tau protein and to propagate in a prion-like manner. However, the exact neurotoxic tau species remain unclear. Because mature tangles seem to be non-toxic component, “tau oligomers” as the candidate of “toxic” tau have been investigated for more than one decade. In this topic, we will discuss our consensus of “tau oligomers” because the term of “tau oligomers” [e.g. dimer (disulfide bond-dependent or independent), multimer (more than dimer), granular (definition by EM or AFM) and maybe small filamentous aggregates] has been used by each researchers definition. From a biochemical point of view, tau protein has several unique characteristics such as natively unfolded conformation, thermo-stability, acid-stability, and capability of post-translational modifications. Although tau protein research has been continued for a long time, we are still missing the mechanisms of NFT formation. It is unclear how the conversion is occurred from natively unfolded protein to abnormally mis-folded protein. It remains unknown how tau protein can be formed filaments [e.g. paired helical filament (PHF), straight filament and twisted filament] in cells albeit in vitro studies confirmed tau self-assembly by several inducing factors. Researchers are still debating whether tau oligomerization is primary event rather than tau phosphorylation in the tau pathogenesis. Inhibition of either tau phosphorylation or aggregation has been investigated for the prevention of tauopathies, however, it will make an irrelevant result if we don’t know an exact target of neurotoxicity. It is a time to have a consensus of definition, terminology and methodology for the identification of “tau oligomers”.

Alzheimer's Disease and Frontotemporal Dementia

Alzheimer's Disease and Frontotemporal Dementia PDF Author: Erik D. Roberson
Publisher: Humana Press
ISBN: 9781607617433
Category : Science
Languages : en
Pages : 0

Get Book Here

Book Description
Alzheimer’s disease and frontotemporal dementia, two of the most prevalent neurodegenerative diseases, are dreaded disorders that attack the neural networks underlying memory and personality, systems that make us who we are. Major breakthroughs in recent years have spurred new research approaches to these conditions. In Alzheimer's Disease and Frontotemporal Dementia: Methods and Protocols, expert investigators bring together the many divergent areas of expertise used to study these diseases, including behavior, electrophysiology, confocal microscopy, and hardcore biochemistry. Beginning with an overview of the two diseases and contemporary research on them, the book continues with specialized protocols for working with amyloid-β peptide, tau, and apolipoprotein E as well as experimental systems for studying AD and FTD, including cell and animal models, and outcome measures that can be used to assess neuronal function in these systems. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easy to use, Alzheimer's Disease and Frontotemporal Dementia: Methods and Protocols serves as an ideal guide for all scientists pursuing the cause and cure of these widespread and nightmarishly debilitating disorders.

Clinical use of biomarkers for neurodegenerative disorders

Clinical use of biomarkers for neurodegenerative disorders PDF Author: Manuel Menéndez-González
Publisher: Frontiers Media SA
ISBN: 2889194000
Category : Biochemical markers
Languages : en
Pages : 123

Get Book Here

Book Description
The prevalence of neurodegenerative disorders is increasing dramatically and one of the major challenges today is the need of early and accurate diagnosis, the other is the need of more effective therapies -in turn the development of such therapies also requires early and accurate diagnosis-. The main hope for an earlier and more accurate diagnosis comes from the use of biomarkers. Much research is being done trying to solve the many interrogates related to the role of biomarkers in clinical practice, including the early diagnosis, differential diagnosis and follow-up of neurodegenerative disorders. This is a field where translational research is intense enough to make this topic interesting for basic researchers and clinicians. Indeed, the amount and quality of articles received in response to the call for contributions was very good. This eBook contains a good amount of high quality articles devoted to diverse techniques across several neurodegenerative disorders from different perspectives, including original reports, reviews, methods reports and opinion letters on biochemical biomarkers in biological fluids, neuroimaging techniques and multidimensional approaches linking clinical findings with biomarkers. The disorders covered are also diverse: Alzheimer’s disease, Frontotemporal Dementia, Dementia with Lewy Bodies, Huntington’s disease, Parkinson’s disease among others. As we can learn from articles in this Research Topic, biomarkers are allowing us to expand the knowledge on the biological and anatomical basis of neurodegenerative diseases and to implement diagnostic techniques in clinical practice and clinical trials.